1-14 of 14
Penka S. Petrova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Steven M. Horwitz, James M. Foran, Michael Maris, Jennifer Kimberly Lue, Ahmed Sawas, Craig Okada, Tatyana A. Feldman, Lubomir Sokol, Matthew Mei, Ian W. Flinn, Diego Villa, Mary-Elizabeth M. Percival, Deepa Jagadeesh, Kerry J. Savage, Oleg Akilov, Catherine S. Diefenbach, Youn H. Kim, Gloria H. Y. Lin, Tina Catalano, Penka S. Petrova, Bob Uger, Naomi Molloy, Kathleen Large, Ingmar Bruns, Stephen M. Ansell
Journal: Blood
Blood (2021) 138 (Supplement 1): 2448.
https://doi.org/10.1182/blood-2021-154490
Published: 2021
Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3560.
https://doi.org/10.1182/blood-2021-153683
Published: 2021
Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-136607
Published: 2020
Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Steven M. Horwitz, MD, James M. Foran, MD, Michael Maris, MD, Ahmed Sawas, MD, Craig Okada, MD PhD, Tatyana A. Feldman, MD, Mark D. Minden, Lubomir Sokol, MD PhD, Matthew Mei, MD, Ian W. Flinn, MD PhD, Diego Villa, MDMPH, Mary-Elizabeth M. Percival, MD, Deepa Jagadeesh, MDMPH, Kerry J. Savage, MDMSc, Oleg E. Akilov, MD PhD, Catherine Diefenbach, MD, Youn H. Kim, MD, Gloria H. Y. Lin, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Bob Uger, PhD, Naomi Molloy, BSc, Kathleen Large, RN, MSN, Yaping Shou, MDPhD, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–43.
https://doi.org/10.1182/blood-2020-136198
Published: 2020
Journal Articles

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew H. Taylor, MD, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Theresa Thompson, Robert A. Uger, PhD, Yaping Shou, MD PhD, Oleg E. Akilov, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1653.
https://doi.org/10.1182/blood-2018-99-116915
Published: 2018
Journal Articles

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Stephen M Ansell, MD PhD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD, PhD, Alexander Lesokhin, MD, Anjali S. Advani, MD, Mark D. Minden, MD PhD, Mary Beth M. Percival, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Meghan Irwin, BSc, EMBA, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD, Robert W. Chen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4116.
https://doi.org/10.1182/blood.V130.Suppl_1.4116.4116
Published: 2017
Journal Articles

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew Taylor, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Meghan Irwin, BSc, EMBA, Eric L Sievers, MD, Oleg E. Akilov, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4076.
https://doi.org/10.1182/blood.V130.Suppl_1.4076.4076
Published: 2017
Journal Articles

Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL

Paraskevi Diamanti, PhD, Saifurrizal Saifurrizal, MD, Charlotte V. Cox, BSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Allison Blair, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3886.
https://doi.org/10.1182/blood.V130.Suppl_1.3886.3886
Published: 2017
Journal Articles

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen Ansell, MD PhD, Robert W Chen, MD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD PhD, Lisa DS Johnson, PhD, Meghan Irwin, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD
Journal: Blood
Blood (2016) 128 (22): 1812.
https://doi.org/10.1182/blood.V128.22.1812.1812
Published: 2016
Journal Articles

Investigating the Effects of Anti-CD200 Therapy for Childhood ALL

Paraskevi Diamanti, BSc, PhD, Charlotte V. Cox, BSc, Benjamin C Ede, BSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Allison Blair, PhD BSc
Journal: Blood
Blood (2016) 128 (22): 4021.
https://doi.org/10.1182/blood.V128.22.4021.4021
Published: 2016
Journal Articles

Preclinical Characterization of TTI-281, a Novel, Orally Bioavailable BET Inhibitor: Predictive Biomarker Identification and Combination Treatment Analysis

Jaehyun Choi, PhD, Chunlei Wang, Zezhou Wang, PhD, Aaron D. Schimmer, MD PhD, Penka S. Petrova, PhD, Malik Slassi, PhD, Robert A. Uger, PhD
Journal: Blood
Blood (2016) 128 (22): 4719.
https://doi.org/10.1182/blood.V128.22.4719.4719
Published: 2016
Journal Articles

TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma

Zezhou Wang, PhD, Jaehyun Choi, PhD, Peter Dove, Chunlei Wang, Aaron D. Schimmer, MD PhD, Penka S. Petrova, PhD, Robert A. Uger, PhD, Malik Slassi, PhD
Journal: Blood
Blood (2016) 128 (22): 2095.
https://doi.org/10.1182/blood.V128.22.2095.2095
Published: 2016
Journal Articles

SIRPαFc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction

Natasja Nielsen Viller, Saman Maleki Vareki, Karen Dodge, Hui Chen, Vivian Lee, Vien Chai, Xinli Pang, Mark Wong, Suzanne Trudel, MD, Rene Figueredo, Macarena Pampillo, James Koropatnick, Penka S. Petrova, Robert A. Uger
Journal: Blood
Blood (2015) 126 (23): 2191.
https://doi.org/10.1182/blood.V126.23.2191.2191
Published: 2015
Journal Articles

Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability

Robert A. Uger, PhD, Xinli Pang, MD, PhD, Mark Wong, PhD, Violetta House, Karen Dodge, Stephane Viau, Noel T. Vigo, Debbie Tam, Tran Truong, Liqing Jin, MD, Andrei V. Malko, Jenny Ho, MD, Tatiana K. Prasolava, PhD, Jayne S. Danska, PhD, Jean C.Y. Wang, MD PhD, Penka S. Petrova, PhD
Journal: Blood
Blood (2013) 122 (21): 3935.
https://doi.org/10.1182/blood.V122.21.3935.3935
Published: 2013